| Literature DB >> 33051451 |
Haiyang Wang1,2,3, Lanxiang Liu3,4, Xuechen Rao2,3, Benhua Zeng5, Ying Yu3, Chanjuan Zhou3, Li Zeng3,6, Peng Zheng3,7, Juncai Pu3,7, Shaohua Xu3, Ke Cheng3,7, Hanping Zhang3,7, Ping Ji1, Hong Wei8, Peng Xie9,10,11.
Abstract
The dysbiosis of gut microbiota is an important environmental factor that can induce mental disorders, such as depression, through the microbiota-gut-brain axis. However, the underlying pathogenic mechanisms are complex and not completely understood. Here we utilized mass spectrometry to identify the global phosphorylation dynamics in hippocampus tissue in germ-free mice and specific pathogen-free mice (GF vs SPF), fecal microbiota transplantation (FMT) model ("depression microbiota" and the "healthy microbiota" recipient mice). As a result, 327 phosphosites of 237 proteins in GF vs SPF, and 478 phosphosites of 334 proteins in "depression microbiota" vs "healthy microbiota" recipient mice were identified as significant. These phosphorylation dysregulations were consistently associated with glutamatergic neurotransmitter system disturbances. The FMT mice exhibited disturbances in lipid metabolism and amino acid metabolism in both the periphery and brain through integrating phosphoproteomic and metabolomic analysis. Moreover, CAMKII-CREB signaling pathway, in response to these disturbances, was the primary common perturbed cellular process. In addition, we demonstrated that the spliceosome, never directly implicated in mental disorders previously, was a substantially neuronal function disrupted by gut microbiota dysbiosis, and the NCBP1 phosphorylation was identified as a novel pathogenic target. These results present a new perspective to study the pathologic mechanisms of gut microbiota dysbiosis related depression and highlight potential gut-mediated therapies for depression.Entities:
Mesh:
Year: 2020 PMID: 33051451 PMCID: PMC7553953 DOI: 10.1038/s41398-020-01024-9
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Fig. 1Stepwise experimental flowchart depicting the analysis of this study.
GF germ-free, SPF specific pathogen-free, FMT-MDD “depression microbiota” recipient mice, FMT-HC “healthy microbiota” recipient mice.
Fig. 2Functional pathways analysis for the significant phosphoproteins using the KOBAS web server based on the KEGG database.
a Functional pathways perturbed in GF vs SPF. b Functional pathways perturbed in FMT-MDD vs FMT-HC.
Fig. 3Functional network construction for the significant phosphoproteins using Ingenuity Pathway Analysis (IPA) software.
a Perturbed pathways in germ-free (GF) mice model. b Perturbed pathways in fecal microbiota transplantation (FMT) mice model. c The visualization of CREB signaling pathway alterd significantly in GF and FMT mice models.
Fig. 4Bioinformatics analysis for the microbial-specific phosphoproteins.
a Canonical pathway analysis for the common phosphoproteins between GF vs SPF and FMT-MDD vs FMT-HC comparisons using Ingenuity Pathway Analysis (IPA) software. b The most significantly disturbed functional network resulting from IPA. c Protein–protein interaction network analysis for these common phosphoproteins.
Differential serum and hippocampal metabolites between FMT-MDD and FMT-HC mice.
| Metabolites | Fold change (con/dep mice) | Changes (dep/con mice) | Metabolic pathways | |
|---|---|---|---|---|
| Glutathione | 0.63 | Down | 2.46E−02 | Amino acid metabolism |
| Pyroglutamic acid | 0.48 | Down | 7.27E−03 | Amino acid metabolism |
| 0.56 | Down | 5.55E−03 | Amino acid metabolism | |
| −0.58 | Up | 4.84E−03 | Carbohydrate metabolism | |
| Palmitic acid | −0.49 | Up | 7.22E−03 | Lipid metabolism |
| −1.11 | Up | 4.14E−06 | Lipid metabolism | |
| Linoleic acid | −0.7 | Up | 2.17E−02 | Lipid metabolism |
| Oleic acid | −0.77 | Up | 2.19E−02 | Lipid metabolism |
| Arachidonic acid (peroxide free) | 0.47 | Down | 1.88E−02 | Lipid metabolism |
| Cholesterol | 1.3 | Down | 2.15E−02 | Lipid metabolism |
| Stearic acid | 0.28 | Down | 1.49E−02 | Lipid metabolism |
| 2-Hydroxyhexadecanoic acid | 0.58 | Down | 3.96E−03 | Lipid metabolism |
| 0.87 | Down | 1.82E−02 | Lipid metabolism | |
| Glycerol-3-phosphoric acid | −1.25 | Up | 9.47E−04 | Not available |
| PC(13:0) | −0.36 | Up | 1.79E−02 | Not available |
| Glycerol-2-phosphoric acid | −0.5 | Up | 1.12E−02 | Not available |
| Indolelactic acid | 0.52 | Down | 3.20E−02 | Not available |
| PGA2 methyl ester | 0.4 | Down | 9.58E−03 | Not available |
| Hydroxyprogesterone acetate | 0.21 | Down | 3.78E−02 | Not available |
| Veratric acid | 0.66 | Down | 5.41E−03 | Not available |
| Sebacic acid | 0.46 | Down | 2.75E−02 | Not available |
| 0.53 | Down | 3.74E−02 | Not available | |
| −1.72 | Up | 7.73E−04 | Amino acid metabolism | |
| 0.41 | Down | 4.99E−03 | Amino acid metabolism | |
| Glycine | 0.17 | Down | 2.24E−02 | Amino acid metabolism |
| Phenylalanine | 0.41 | Down | 5.88E−03 | Amino acid metabolism |
| Leucine | 0.52 | Down | 8.03E−03 | Amino acid metabolism |
| α- | −0.75 | Up | 5.98E−04 | Carbohydrate metabolism |
| −0.89 | Up | 4.99E−04 | Carbohydrate metabolism | |
| Malic acid | −0.71 | Up | 1.61E−03 | Carbohydrate metabolism |
| Linolenic acid ethyl ester | −0.13 | Up | 2.49E−02 | Lipid metabolism |
| Myristic acid | −0.26 | Up | 2.01E−02 | Lipid metabolism |
| Palmitic amide | −0.17 | Up | 6.82E−03 | Lipid metabolism |
| Ricinoleic acid methyl ester | −0.26 | Up | 5.39E−03 | Lipid metabolism |
| 1-Monopalmitin | −0.24 | Up | 2.64E−03 | Lipid metabolism |
| 0.18 | Down | 4.43E−01 | Lipid metabolism | |
| Phytosphingosine | −0.13 | Up | 2.42E−02 | Lipid metabolism |
| PGF2α dimethyl amide | −0.5 | Up | 2.61E−04 | Not available |
| dihydrotachysterol | −0.13 | Up | 4.02E−02 | Not available |
| Glucoheptonic acid | −0.79 | Up | 1.31E−04 | Not available |
| β-Hydroxy-β-methylglutaric acid | 0.28 | Down | 2.86E−02 | Not available |
Fig. 5Integrated phosphoproteomic analysis of depressive rodents and patients with major depression disorders.
a Venn diagram showing the number of overlapped and specific phosphoproteins across depressive mice, rats, and patients with major depression disorder. b Detailed information of the overlapped phosphoproteins identified as significantly changing across all phosphoproteomic screens. c Functional enrichment analysis results for all these overlapped phosphoproteins using KOBAS web server.